What question did this study set out to answer?

The research aims to explore the potential of S. cerevisiae as a therapeutic agent for vulvovaginal candidiasis.

April 17, 2026Expert Review of Anti-infective Therapy0 citations

Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?

MSMart SillenUniversity of Antwerp SBSilke BaldewijnsInstitute of Botany PVPaul VandecruysInstitute of Botany

Key Points

The research aims to explore the potential of S. cerevisiae as a therapeutic agent for vulvovaginal candidiasis.
Evaluation of S. cerevisiae treatment's effectiveness at preventing Candida infections
Assessment of integration into combination therapies
Focus on optimizing strain-specific applications
S. cerevisiae shows promise in reducing recurrence of Candida infections
It complements existing antifungal and host-directed therapies
Potential for maintaining mucosal homeostasis in affected individuals

Abstract

S. cerevisiae treatment will play a role in both the prevention of recurrence/occurrence of Candida infections and the integration into combination regimens, where they can complement antifungal and host-directed therapies rather than function as standalone treatments. Future advances will depend on patient stratification, strain-specific optimization, and the integration of microbial therapies into combination treatment frameworks aimed at restoring and maintaining mucosal homeostasis.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Sillen et al. (Tue,) studied this question.

synapsesocial.com/papers/69e1ce065cdc762e9d857227 https://doi.org/https://doi.org/10.1080/14787210.2026.2659774

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI से पूछें

Bookmark

View Full Paper